Professor du Souich: “Chondroitin sulfate, alone or combined with glucosamine, could actually delay knee OA progression and the need for replacement surgery”According to the president of the International Union of Pharmacy (IUPHAR), Professor Patrick du Souich, from the University of Montreal, widespread use of that drug could bring important improvements to the life quality of OA patients, as well as significant reduction costs for our national healthcare services
Along the same lines, Professor Jean- Pierre Pelletier, from the University of Montreal, presented a clinical essay that concluded that chondroitin sulfate protects from cartilage volume loss, thus saving many knee OA and synovitis patients from undergoing replacement surgery.
Both experts took part in the symposium “Treatment Success in Osteoarthritis: Advances in Pharmacologic Therapy”, sponsored by Biobérica Farma, the only Spanish company that has sponsored a symposium during the Annual Meeting of the American Academy of Rheumatology that is taking place in Washington
